Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition
9 May 2026 – 14 May 2026 · Cape Town, South Africa
663-03-003 ISMRM Abstract

Glymphatic clearance partially mediates the relationship between amyloid and tau deposition in Alzheimer’s disease

Primary: Neuro - Neurofluids
Secondary: Neuro - Alzheimer's Disease
663-03-003 · Glymphatic System Imaging: From Neurofluid Transport to Neurodegeneration · Thursday, 14 May, 1:40 PM–2:35 PM · Digital Posters Row D
Keywords: T2 relaxometry Mediation analysis Amyloid PET Glymphatic clearance Parenchymal cerebrospinal fluid mapping
Accepted
Liangdong Zhou 1, Tracy A Butler1, Samantha A Keil, Xiuyuan H Wang1, Seyed Hani Hojjati, Tsung-wei Hu1, Lidia Glodzik1, Thanh D Nguyen1, Gloria C Chiang1, Yi Li1
1Department of Radiology, Weill Cornell Medicine, New York, United States of America
Presenting Author: Liangdong Zhou

Synopsis

Motivation:
Goals:
Approach:
Results:
Full abstract & presentation

The full text, figures, and any recorded presentation for this abstract are not shown here. Log in if you are a member or registered attendee with access.

Full abstracts, figures, and presentations for Cape Town - 2026 ISMRM-ISMRT Annual Meeting and Exhibition are available to registered attendees. This content becomes freely available to the public roughly two years after the meeting.

To request or purchase access, contact the ISMRM Central Office at info@ismrm.org.

Log in

References

1. 1. De Leon MJ, George AE, Golomb J, et al. Frequency of hippocampal formation atrophy in normal aging and Alzheimer’s disease. Neurobiology of Aging. 1997;18(1):1-11. doi:10.1016/S0197-4580(96)00213-8 [doi]
2. 2. Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006;12(7):856-861. doi:10.1038/nm1438 [doi]
3. 3. Barthel H. First Tau PET Tracer Approved: Toward Accurate In Vivo Diagnosis of Alzheimer Disease. Journal of Nuclear Medicine. 2020;61(10):1409-1410. doi:10.2967/jnumed.120.252411 [doi]
4. 4. Li Y, Rusinek H, Butler T, et al. Decreased CSF clearance and increased brain amyloid in Alzheimer’s disease. Fluids and Barriers of the CNS. 2022;19(1):21. doi:10.1186/s12987-022-00318-y [doi]
5. 5. Zhou L, Nguyen TD, Chiang GC, et al. Parenchymal CSF fraction is a measure of brain glymphatic clearance and positively associated with amyloid beta deposition on PET. Alzheimer’s & Dementia. 2024;20(3):2047-2057. doi:10.1002/alz.13659 [doi]
6. 6. Mehta NH, Wang X, Keil SA, et al. [1-11C]-Butanol Positron Emission Tomography reveals an impaired brain to nasal turbinates pathway in aging amyloid positive subjects. Fluids Barriers CNS. 2024;21(1):30. doi:10.1186/s12987-024-00530-y [doi]
7. 7. Roda AR, Serra-Mir G, Montoliu-Gaya L, Tiessler L, Villegas S. Amyloid-beta peptide and tau protein crosstalk in Alzheimer’s disease. Neural Regen Res. 2022;17(8):1666-1674. doi:10.4103/1673-5374.332127 [doi]
8. 8. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer’s disease: an appraisal for the development of therapeutics. Nat Rev Drug Discov. 2011;10(9):698-712. doi:10.1038/nrd3505 [doi]
9. 9. Lopes DM, Wells JA, Ma D, et al. Glymphatic inhibition exacerbates tau propagation in an Alzheimer’s disease model. Alzheimer’s Research & Therapy. 2024;16(1):71. doi:10.1186/s13195-024-01439-2 [doi]
10. 10. Raj A, Torok J, Ranasinghe K. Understanding the complex interplay between tau, amyloid and the network in the spatiotemporal progression of Alzheimer’s disease. Prog Neurobiol. 2025;249:102750. doi:10.1016/j.pneurobio.2025.102750 [doi]
11. 11. Arnsten AFT, Del Tredici K, Barthélemy NR, et al. An integrated view of the relationships between amyloid, tau, and inflammatory pathophysiology in Alzheimer’s disease. Alzheimer’s & Dementia. 2025;21(8):e70404. doi:10.1002/alz.70404 [doi]
12. 12. Iliff JJ, Wang M, Liao Y, et al. A Paravascular Pathway Facilitates CSF Flow Through the Brain Parenchyma and the Clearance of Interstitial Solutes, Including Amyloid β. Science Translational Medicine. 2012;4(147):147ra111-147ra111. doi:10.1126/scitranslmed.3003748 [doi]
13. 13. Benveniste H, Liu X, Koundal S, Sanggaard S, Lee H, Wardlaw J. The Glymphatic System and Waste Clearance with Brain Aging: A Review. GER. 2019;65(2):106-119. doi:10.1159/000490349 [doi]
14. 14. Harrison IF, Ismail O, Machhada A, et al. Impaired glymphatic function and clearance of tau in an Alzheimer’s disease model. Brain. 2020;143(8):2576-2593. doi:10.1093/brain/awaa179 [doi]
15. 15. Zhou L, Li Y, Sweeney EM, et al. Association of brain tissue cerebrospinal fluid fraction with age in healthy cognitively normal adults. Front Aging Neurosci. 2023;Vol. 15(1162001). doi:10.3389/fnagi.2023.1162001 [doi]
16. 16. Zhou L, Nguyen TD, Chiang GC, et al. Brain glymphatic fluid mapping in Alzheimer’s disease: a human MRI and PET study. Brain Commun. 2025;7(3):fcaf200. doi:10.1093/braincomms/fcaf200 [doi]
17. 17. Nguyen TD, Deh K, Monohan E, et al. Feasibility and reproducibility of whole brain myelin water mapping in 4 minutes using fast acquisition with spiral trajectory and adiabatic T2prep (FAST-T2) at 3T: Whole Brain Myelin Water Mapping with FAST-T2. Magn Reson Med. 2016;76(2):456-465. doi:10.1002/mrm.25877 [doi]
18. 18. Mosconi L, Rinne JO, Tsui WH, et al. Increased fibrillar amyloid-β burden in normal individuals with a family history of late-onset Alzheimer’s. Proceedings of the National Academy of Sciences. 2010;107(13):5949-5954. doi:10.1073/pnas.0914141107 [doi]
19. 19. Braak H, Alafuzoff I, Arzberger T, Kretzschmar H, Del Tredici K. Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry. Acta Neuropathol. 2006;112(4):389-404. doi:10.1007/s00401-006-0127-z [doi]
20. 20. Macedo AC, Tissot C, Therriault J, et al. The Use of Tau PET to Stage Alzheimer Disease According to the Braak Staging Framework. J Nucl Med. 2023;64(8):1171-1178. doi:10.2967/jnumed.122.265200 [doi]
21. 21. Shrout PE, Bolger N. Mediation in experimental and nonexperimental studies: new procedures and recommendations. Psychol Methods. 2002;7(4):422-445.
22. 22. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation: R Package for Causal Mediation Analysis. Journal of Statistical Software. 2014;59:1-38. doi:10.18637/jss.v059.i05 [doi]
23. 23. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: Standardizing Quantitative Amyloid Plaque Estimation by PET. Alzheimers Dement. 2015;11(1):1-15.e4. doi:10.1016/j.jalz.2014.07.003 [doi]

Cite this abstract

http://echo.ismrm.org/p/ISMRM2026/663-03-003